DelveInsight’s, “Non-Muscle Invasive Bladder Cancer Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Non-Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non-Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Non-Muscle Invasive Bladder Cancer Pipeline Report
- DelveInsight’s Non-Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Non Muscle Invasive Bladder Cancer treatment.
- The leading companies working in the Non-Muscle Invasive Bladder Cancer Market include Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
- Promising Non-Muscle Invasive Bladder Pipeline Therapies in the various stages of development include CG0070, n-dodecyl-B-D-maltoside, Durvalumab, BCG, cis-UCA solution, and others.
- December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab and BCG. This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B). The primary hypothesis for Cohort A is that the combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central pathology review compared to BCG in participants with carcinoma in situ (CIS).
- December 2023: Janssen Research & Development LLC announced a study of Phase 2 clinical trials for Erdafitinib. The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator’s Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.
- September 2023: Protara Therapeutics announced a study of phase 1 & 2 clinical trials for TARA-002. The Phase 1b/2 study (TARA-002-101-Ph1b/2) will be initiated after the RP2D has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 1b/2 (TARA-002-101-Ph1b/2) dose expansion study includes participants with CIS NMIBC (± Ta/T1) with active disease (defined as disease present at last tumor evaluation prior to signing ICF).
- September 2023: Pfizer announced a study of phase 3 clinical trials for PF-06801591 and Bacillus Calmette-Guerin. The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B).
Request a sample and discover the recent advances in Non-Muscle Invasive Bladder Cancer Treatment Drugs @ Non-Muscle Invasive Bladder Cancer Pipeline Report
In the Non-Muscle Invasive Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Non-Muscle Invasive Bladder Cancer Overview
Non muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. It is a cancer found in the tissue that lines the inner surface of the bladder. Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored.
Find out more about Non-Muscle Invasive Bladder Cancer Therapeutics Assessment @ Non-Muscle Invasive Bladder Cancer Preclinical and Discovery Stage Products
Non-Muscle Invasive Bladder Cancer Emerging Drugs Profile
- APL-1202: Asieris Pharmaceuticals
- Pemigatinib: Incyte Corporation
- VAX 014: Vaxiion Therapeutics
Non-Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Non Muscle Invasive Bladder Cancer therapies. The Non Muscle Invasive Bladder Cancer companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, Asieris Pharmaceuticals.
Learn more about the emerging Non-Muscle Invasive Bladder Cancer Pipeline Therapies @ Non-Muscle Invasive Bladder Cancer Clinical Trials Assessment
Scope of the Non-Muscle Invasive Bladder Cancer Pipeline Report
- Coverage- Global
- Non-Muscle Invasive Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Non-Muscle Invasive Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Non-Muscle Invasive Bladder Cancer Companies- Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
- Non-Muscle Invasive Bladder Pipeline Therapies- CG0070, n-dodecyl-B-D-maltoside, Durvalumab, BCG, cis-UCA solution, and others.
Dive deep into rich insights for new drugs for Non-Muscle Invasive Bladder Cancer Treatment, Visit @ Non-Muscle Invasive Bladder Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Non Muscle Invasive Bladder Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Non Muscle Invasive Bladder Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- APL-1202: Asieris Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Pemigatinib: Incyte Corporation
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- VAX 014: Vaxiion Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Non Muscle Invasive Bladder Cancer Key Companies
- Non Muscle Invasive Bladder Cancer Key Products
- Non Muscle Invasive Bladder Cancer- Unmet Needs
- Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
- Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
- Non Muscle Invasive Bladder Cancer Analyst Views
- Non Muscle Invasive Bladder Cancer Key Companies
- Appendix
For further information on the Non-Muscle Invasive Bladder Cancer Pipeline therapeutics, reach out to Non-Muscle Invasive Bladder Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market